Omnicell (NASDAQ:OMCL) Shares Gap Up – What’s Next?

Omnicell, Inc. (NASDAQ:OMCL) shares gapped up before the market opened on Wednesday . The stock had previously closed at $28.00, but opened at $29.48. Omnicell shares last traded at $29.16, with a volume of 106,273 shares trading hands.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on OMCL shares. Benchmark cut their target price on shares of Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Wells Fargo & Company upgraded shares of Omnicell from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $31.00 to $35.00 in a research note on Wednesday. JPMorgan Chase & Co. lowered their price objective on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th. Finally, StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday, May 3rd. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Omnicell currently has an average rating of “Hold” and a consensus target price of $46.50.

Omnicell Trading Down 2.3%

The stock’s 50 day moving average price is $31.57 and its 200-day moving average price is $39.64. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.32 billion, a PE ratio of 104.00, a PEG ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.10. The firm had revenue of $269.67 million during the quarter, compared to analysts’ expectations of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.03 earnings per share. On average, sell-side analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omnicell

Institutional investors have recently bought and sold shares of the stock. Smartleaf Asset Management LLC grew its stake in shares of Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after buying an additional 273 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in Omnicell by 6.9% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company’s stock valued at $213,000 after buying an additional 307 shares in the last quarter. Van ECK Associates Corp lifted its holdings in Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after buying an additional 315 shares in the last quarter. First Horizon Advisors Inc. increased its position in Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after purchasing an additional 355 shares during the period. Finally, Redmond Asset Management LLC increased its position in Omnicell by 0.3% during the 4th quarter. Redmond Asset Management LLC now owns 121,209 shares of the company’s stock valued at $5,396,000 after purchasing an additional 371 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.